Author

Devyani Joshi

Emory UniversityORCID 0000-0001-5285-7725Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

Jens WrammertiD· 3 shared Alberto Moreno· 2 shared Lilin LaiiD· 2 shared Mehul S. SuthariD· 2 shared Sanjeev KumariD· 2 shared Veronika I. ZarnitsynaiD· 2 shared Adam J. GilbertseniD· 1 shared Allison R BurrelliD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Jens WrammertORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 30, 2026

Distinct Longitudinal Antibody Responses Following Primary Influenza Infection or Vaccination in Infants: A Prospective Birth Cohort Study

Devyani Joshi, Sanjeev Kumar, Veronika I. Zarnitsyna…·Jens Wrammert

This study compares antibody responses in infants after influenza infection or vaccination, finding greater post-exposure responses following infection compared to vaccination.

DOI 10.64898/2026.09.28.755012

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologyJournal of VirologyPeer-reviewedAug 26, 2026

Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses

Sanjeev Kumar, Lilin Lai, Madison Ellis…·Mehul S. Suthar

This study evaluates antibody responses after a KP.2 spike mRNA vaccine dose, showing durable and broadly cross-reactive immunity against multiple SARS-CoV-2 variants, but reduced neutralizing activity against some emerging subvariants.

2 citationstop 2%

humanproteomics

𝕏 PostBluesky

ImmunologymBioPeer-reviewedJul 6, 2026

Dirty mice better recapitulate key features of mRNA vaccine immunogenicity observed in humans

Beatriz Praena, Frances K. Shepherd, Cera A. McDonald…·Ryan Andrew Langlois

This study shows that dirty mice, with broad microbial exposure, better model human immune responses to SARS-CoV-2 mRNA vaccines, showing reduced antibody titers and faster waning compared to SPF mice.

DOI 10.1128/mbio.00983-26

mouseexperimental assay

𝕏 PostBluesky